
    
      A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the
      Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral
      Corticosteroid Dependent Asthma
    
  